Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is driven by unresolved pulmonary arterial thrombi and involves complex processes such as vascular remodeling and immune dysregulation. Early identification of molecular markers may support more accurate diagnosis and individualized therapy.
Methods: We integrated anthropometric and biochemical data with single-cell RNA sequencing (scRNA-seq), DNA methylation, and Mendelian randomization (MR) analyses. scRNA-seq data were analyzed to determine altered cell populations and pathways. MR and colocalization analyses were conducted to identify genetically supported candidates related to CTEPH.
Results: scRNA-seq analysis revealed altered immune composition, with a modest increase in NK cells and an angiogenesis-associated enrichment of monocytes and HSC-G-CSF cells in CTEPH patients, accompanied by activation of toll-like receptor and MAPK signaling pathways. MR and colocalization identified several genetically associated genes—CLEC7A, TNFSF13B, LRP1, ETS1, and FGR—of which ETS1 and FGR demonstrated good diagnostic performance. DNA methylation analysis indicated marked alterations in chromatin assembly and epigenetic regulation.
Conclusions: This multi-omics study highlights critical genes, epigenetic features, and immune-related cell populations associated with CTEPH. These findings improve understanding of disease mechanisms and offer potential biomarkers for early diagnosis and personalized management.
| [1] |
Escal J, Poenou G, Delavenne X, et al. Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH. Blood Rev. 2024; 68:101240.
|
| [2] |
Kopeć G, Forfia P, Abe K, et al. Recognition, diagnosis, and operability assessment of chronic thromboembolic pulmonary hypertension (CTEPH): a global cross-sectional scientific survey (CLARITY). Pulm Circ. 2024; 14(1):e12330.
|
| [3] |
Biondi F, Alberti M, Montemaggi E, D'Alleva A, Madonna R. Not just CTEPH: a narrative review on the Spectrum approach to postpulmonary embolism conditions. Thromb Haemost. 2024; 125: 634-642.
|
| [4] |
Yang JZ, Poch DS, Ang L, Mahmud E, Kim NH. Balloon pulmonary angioplasty in the current era of CTEPH treatment: how did we get here? Pulm Circ. 2023; 13(4):e12312.
|
| [5] |
Madden BP. Pulmonary hypertension. Eur Cardiol. 2015; 10(1): 9-11.
|
| [6] |
Barnes H, Brown Z, Burns A, Williams T, Cochrane Airways Group. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev. 2019; 1(1):Cd012621.
|
| [7] |
Arunthari V, Burger CD. Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension. Open Respir Med J. 2009; 3: 85-89.
|
| [8] |
Manders E, Bonta PI, Kloek JJ, et al. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016; 311(1): L20-L28.
|
| [9] |
Dzikowska-Diduch O, Kurnicka K, Lichodziejewska B, et al. Electrocardiogram, echocardiogram and NT-proBNP in screening for thromboembolism pulmonary hypertension in patients after pulmonary embolism. J Clin Med. 2022; 11(24):7369.
|
| [10] |
Lin J, Lin S, Zhang Y, Liu W. Identification of Ferroptosis-related potential biomarkers and immunocyte characteristics in chronic thromboembolic pulmonary hypertension via bioinformatics analysis. BMC Cardiovasc Disord. 2023; 23(1): 504.
|
| [11] |
Wang F, Sun C, Lv X, et al. Identification of a novel gene correlated with vascular smooth muscle cells proliferation and migration in chronic thromboembolic pulmonary hypertension. Front Physiol. 2021; 12:744219.
|
| [12] |
Zhang F, Huang X, Lin J, et al. Identification of a novel diagnosis model based on 5 hub genes for chronic thromboembolic pulmonary hypertension. Curr Med Chem. 2024; 31(13): 1754-1768.
|
| [13] |
Feng X, Wang K, Yang T, Dang B, Wang X. Overexpressed microRNA (miR)-382-3p promoted vascular remodeling via suppressing autophagy-related protein 7 (ATG7) in chronic thromboembolic pulmonary hypertension. Curr Mol Med. 2023.
|
| [14] |
Willems L, Kurakula K, Verhaegen J, et al. Angiogenesis in chronic thromboembolic pulmonary hypertension: a Janus-faced player? Arterioscler Thromb Vasc Biol. 2024; 44(4): 794-806.
|
| [15] |
Smadja DM, Mauge L, Sanchez O, et al. Distinct patterns of circulating endothelial cells in pulmonary hypertension. Eur Respir J. 2010; 36(6): 1284-1293.
|
| [16] |
Müller F, Scherer M, Assenov Y, et al. RnBeads 2.0: comprehensive analysis of DNA methylation data. Genome Biol. 2019; 20(1):55.
|
| [17] |
Zhu Z, Zhang F, Hu H, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016; 48(5): 481-487.
|
| [18] |
Lachant DJ, Bach C, Fe A, White RJ, Lachant NA. Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. ERJ Open Res. 2021; 7(1): 00554-2020.
|
| [19] |
Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7): 568-570.
|
| [20] |
Smolders V, Rodríguez C, Blanco I, et al. Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Sci Rep. 2022; 12(1):2283.
|
| [21] |
Yang J, Madani MM, Mahmud E, Kim NH. Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest. 2023; 164(2): 490-502.
|
| [22] |
Valenta I, Dilsizian V, Quercioli A, Schelbert HR, Schindler TH. The influence of insulin resistance, obesity, and diabetes mellitus on vascular tone and myocardial blood flow. Curr Cardiol Rep. 2012; 14(2): 217-225.
|
| [23] |
Wang W, Liu J, Yang YH, Zhai ZG, Wang C, Wang J. Red cell distribution width is increased in chronic thromboembolic pulmonary hypertension. Clin Respir J. 2016; 10(1): 54-60.
|
| [24] |
Gong J, Yang Y, Wang J, et al. Expression of miR-93-5p as a potential predictor of the severity of chronic thromboembolic pulmonary hypertension. Biomed Res Int. 2021; 2021:6634417.
|
| [25] |
Xi Q, Liu Z, Song Y, et al. Proteomic analyses of Endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension. Cardiology. 2020; 145(1): 48-52.
|
| [26] |
Wu D, Lin Y, Yang M, et al. Tissue factor regulates autophagy in pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension rats via the p38 MAPK-FoxO1 pathway. Respir Res. 2024; 25(1):261.
|
RIGHTS & PERMISSIONS
2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences
PDF
(3567KB)
